Hepatocellular Carcinoma, Lung Cancer, Solid Tumor
Conditions
Brief summary
To study the safety and clinical effects of intratumor injecting CpG-ODN and in situ release of tumor antigen by interventional ablation or drug-eluting beads to treat advanced solid tumors.
Detailed description
1. Percutaneous microwave ablation or intratumor injection of drug-eluting beads to destroy cancer cells to release tumor-specific antigens 2. Intratumor injection of type A/C CpG-ODN with or without infusion of CAR-T cells secreting scFv against OX40 3. Assessing side effects and therapeutic efficacy after the combined treatments
Interventions
COMBINATION_PRODUCTCpG-ODN
CAR-T cells secreting scFv against OX40
Sponsors
Guangdong Zhaotai InVivo Biomedicine Co. Ltd.
Second Affiliated Hospital of Guangzhou Medical University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Solid advanced malignant tumors * Age between18 and 80 years * Life expectancy is greater than three months
Exclusion criteria
* Benign tumor * Life expectancy is less than three months * Serious medical comorbidity * Others
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Assessing safety and treatment efficacy on intratumor injection of CpG-ODN and in situ tumor antigen release for advanced tumors | up to 36 months | Assessing incidence of side effects and primary clinical response of the intratumor injection of CpG-ODN and therpeutical in situ tumor antigen release for advanced tumors, including CR, PR, SD, and PD. |
Countries
China
Contacts
Primary ContactZhenfeng Zhang, MD, PhD
Backup ContactBingjia He, MD
Outcome results
None listed